{
    "id": 31629,
    "fullName": "ZNF217 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "ZNF217 over exp indicates an over expression of the Znf217 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 7764,
        "geneSymbol": "ZNF217",
        "terms": [
            "ZNF217",
            "ZABC1"
        ]
    },
    "variant": "over exp",
    "createDate": "11/22/2019",
    "updateDate": "11/22/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19275,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Triciribine (API-2) treatment inhibited Akt and Mapk phosphorylation, resulted in tumor growth inhibition in mouse models of a mouse breast cancer cell line overexpressing Znf217 (PMID: 22728437).",
            "molecularProfile": {
                "id": 34002,
                "profileName": "ZNF217 over exp"
            },
            "therapy": {
                "id": 948,
                "therapyName": "Triciribine",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16874,
                    "pubMedId": 22728437,
                    "title": "The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22728437"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19276,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, addition of Triciribine (API-2) restored sensitivity to Adriamycin (doxorubicin) treatment in breast cancer cells overexpressing Znf703 in culture (PMID: 22728437).",
            "molecularProfile": {
                "id": 34002,
                "profileName": "ZNF217 over exp"
            },
            "therapy": {
                "id": 8981,
                "therapyName": "Doxorubicin + Triciribine",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16874,
                    "pubMedId": 22728437,
                    "title": "The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22728437"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 34002,
            "profileName": "ZNF217 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}